Autres langues Shilpa Medicare Limited

Actions

SHILPAMED

INE790G01031

Marché Fermé - Bombay S.E. Autres places de cotation 12:00:53 15/07/2024			Varia. 5j.	Varia. 1 janv.
654 ^INR	-0,84 %		-0,91 %	+97,94 %

10/07	Le site de production d'ingrédients pharmaceutiques actifs de Shilpa Pharma Lifesciences à Karnataka, en Inde, passe l'inspection de l'organisme brésilien de réglementation des médicaments	MT
09/07	Shilpa Medicare recevra des actions de sa filiale en guise de paiement de prêt	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Shilpa Medicare Arm's API Facility in Karnataka, India, Passes Brazilian Drug Regulator's Inspection	10/07
Shilpa Medicare to Receive Shares from Unit as Loan Payment	09/07
Shilpa Medicare Shares Rally 16% as Client Reports Positive Clinical Trial Results	05/07
INDIA STOCKS-HDFC Bank drags Indian shares as rally to record highs takes pause	05/07
Unicycive Therapeutics, Inc. Enters into First Amendment to Manufacturing and Supply Agreement with Shilpa Medicare, Ltd	02/07
Shilpa Medicare Bio Analytical Unit Gets "No Action Indicated" Classification from US FDA	25/06
Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	23/05
Shilpa Medicare Limited Announces Successful Completion of Early Clinical Development and Ongoing Phase 3 Clinical Trial of Its Newly Developed Drug "SML-007", for the Treatment of Non-Alalcoholic Fatty Liver Disease	14/05
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	18/04
Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit	17/04
Shilpa Medicare Gets Board Nod to Launch QIP	09/04
Shilpa Medicare's Life Science Arm Names CEO	28/03
Shilpa Medicare's New Unit in Hyderabad, India Gets Zero Observations from US FDA	01/03
Shilpa Medicare Gets Approval to Market Smoking Cessation Drug in Europe	26/02
Shilpa Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02
Shilpa Medicare Gets Germany's Marketing Approval for Rare Muscles Diseases Drug	19/01
Shilpa Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	10/11
Shilpa Medicare Acquires US-Based Pilnova Pharma	03/11
Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal	11/10/23
Shilpa Medicare Unit's API Manufacturing Plant Gets Clearance from Japanese Drug Regulator's Inspection	04/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Shilpa Medicare Limited

Actions

SHILPAMED

INE790G01031

Autres langues

Filtres